{"database": "lobbying", "table": "lobbying_activities", "rows": [[2824558, "b0ffeaa9-e4dc-4860-a099-8aaf83936f10", "Q2", "RICCHETTI INCORPORATED", 62778, "NEUROCRINE BIOSCIENCES, INC.", 2022, "second_quarter", "MMM", "Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related Medicare Part D reform and its impact on Low Income Subsidy (LIS) patients", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2022-07-18T14:14:23-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2824558"], "units": {}, "query_ms": 0.753542990423739, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}